key: cord-0816242-fs0sasfy
authors: Bharat, Ankit; Hoetzenecker, Konrad; Machuca, Tiago N
title: Lung transplantation for COVID-19-associated ARDS – Authors' reply
date: 2021-07-02
journal: Lancet Respir Med
DOI: 10.1016/s2213-2600(21)00288-5
sha: 1a7731c1ed43e70f9628e4ad504536b79efeae8f
doc_id: 816242
cord_uid: fs0sasfy

nan

Although lung parenchyma can recover after extended durations of extracorporeal membrane oxygenation (ECMO), as emphasised by Jonathan Messika and colleagues, the in-hospital mortality of patients with COVID-19-associated ARDS requiring ECMO remains as high as 40-50%. 4 Additionally, post-discharge mortality after severe COVID-19associated ARDS is also substantial. 5 Consistent with published reports, we have observed numerous patients become increasingly ill and confined to rehabilitation centres, ultimately succumbing to respiratory complications. Hence, our approach is to continue supporting patients with medical therapies as long as lung recovery remains likely, without pre-determined time cutoffs. When recovery is deemed unlikely, we consider transplantation before lethal complications arise. Our published scientific report identified potential biomarkers of lung recoverability. 2 However, because clinical availability of these biomarkers is limited, assessment of lung recoverability requires careful evaluation of pulmonary physiology, radiology, histology (when available), patient medical course and complications, response to therapies, and many other clinical factors by an experienced multidisciplinary care team. We also believe that consideration of transplantation sooner than 4 weeks after the onset of ARDS is premature, except in rare cases in which patients develop medically refractory complications.

We strongly disagree with the proposal to set the lung allocation score to 0 for patients with ARDS. The main purpose of the score is to reflect the urgency and severity of an illness. Denying a life-saving treatment to this population would be a disservice and, in our view, unethical. Lung transplantation for patients with COVID-19-associated ARDS is not an option for every patient and should not be done at all centres. It is our responsibility to determine how to navigate the delivery of a resourceconstrained therapy based on our best understanding of programmatic resources, patient selection, and posttransplantation outcomes.

We declare no competing interests.

abharat@nm.org

Lung transplantation for patients with severe COVID-19

Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study

Sixty-day outcomes among patients hospitalized with COVID-19